



## Suspecting inherited thrombocytopenia

#### Maria L Lozano

Department of Hematology
Hospital General Universitario Morales Meseguer
University of Murcia
Murcia— Spain
11 October 2023

ERN-EuroBloodNet Topic on Focus: Constitutional

thrombocytopenia









Research support/PI	Amgen
Employee	-
Consultant / Honoraria	Amgen, Argenx, Grifols, Novartis, Sobi, UCB
Major stockholder	-
Speaker's fees	Amgen, Grifols, Novartis, Sobi
Scientific advisory board	Amgen, Argenx, Grifols, Novartis, Sobi, UCB







#### **Learning objectives of the webinar**



- 1. Become familiar with the major types of inherited thrombocytopenia and their variable presentation.
- 2. Avoid misdiagnosis of inherited thrombocytopenia with immune thrombocytopenia
- 3. Understand the need to recognize and investigate forms that predispose to other diseases








## Inherited defects of selected genes cause thrombocytopenia








Network
 Hematological
 Diseases (ERN EuroBloodNet)

**MHEMO** 





## Chromosomal syndromes associated with thrombocytopenia



Chromosomal alteration	Incidence	Clinical manifestations	Incidence of thrombocytopenia
Trisomy 21	1 in 660	Cognitive retardation, hearing impairment, thyroid problems, heart defects, gastroenterological atresia, cataracts	7-28%
Trisomy 13	1 in 5000	Cleft lip and cleft palate; polydactyly, foot malformations; umbilical hernia; cardiac septal defects; ductus arteriosus; neural tube defects	54%
Trisomy 18	1 in 5000	Dolicocephaly, micrognathia, alterations in fingers, cardiac septal defects, renal, psychomotor retardation	86%
Turner síndrome (45, X)	1 in 2500	Coarctation of aorta, stenosis, short stature, ovarian failure, horseshoe kidney, ulnar valgus, low posterior capillary line, winged neck	31%
Di George síndrome (22q11.2 del) (AD)	1 in 4000	Typical facies, thymic abnormalities, hypocalcemia, velopharyngeal insufficiency, cardiac defects	30%
Jacobsen/Paris Trousseau syndrome [Del(11)(q23.3)] (AD)	1 in 100 000	Dysmorphogenesis of the hands and feet, cardiac defects and cognitive retardation	88%








#### Frequency of deleterious variants in genes associated to inherited thrombocytopenia



#### Calculated frequency of predisposition to platelet disorders/10<sup>5</sup> population



In the general population, 0.329% of individuals have a clinically meaningful predicted loss-of-function variant in a gene associated to inherited platelet disorders



Diseases (ERN EuroBloodNet)





## Classification of inherited thrombocytopenia



	Only thrombocytopenia
	Bernard Soulier síndrome (BSS)
$\vdash$	Monoallelic BSS
$\vdash$	ACTN1-RT
	Gray platelet syndrome
	Platelet type vWD
	GFI1b-RT
	TUBB1-RT
	ITGA2B/ITGB3-RT
	CYCS-RT
	SLFN14-RT
	FLI1-RT
	IKZF5-RT
	TRPM7-RT
	TPM4-RT
	PTPRJ-RT
Euro	PRKACG-RT
Refe	
for rare complex	low prevalence G6B
Network Hematol	

Syndromic forms
Wiskott-Aldrich; XLT
SD Paris-Trousseau/Jacobsen (FLI1)
Thrombocytopenia absent radii
GATA1-RT
ARPC1B-RT
Stormorken/York syndromes
Takenouchi-Kosaki syndrome
KDSR-RT
ACTB-RT
FLNA-RT
MPIG6B-RT
GALE-RT
GNE-RT

Predisp	position to additional disorders
-	MYH9-RD
	ANKRD26
	FPD/AML
	ETV6-RT
-	CAMT (MPL)
-	CAMT (THPO)
-	MECOM-RT
-	RUSAT (HOXA11)
	DIAPH1-RT
	SRC-RT
	Sitosterolemia



## When to suspect inherited thrombocytopenia



## Step 1. Clinical presentation

- Family history of thrombocytopenia or hematological malignancies
- Excessive bleeding for platelet counts
- Refractory immune thrombocytopenia (ITP)
- Von Willebrand disease
- Additional findings


## Step 2. Biological features

- Platelet counts and mean platelet volume
- Immature platelet fraction
- Blood smear
- Defects in other cell populations



#### Step 1 (Clinical presentation): syndromic phenotype of thrombocytopenias







Network
 Hematological
 Diseases (ERN EuroBloodNet)


#### Step 1 (clinical presentation): tools to quantify bleeding



Bleeding Assessment Tools (BAT) have been developed to standardize bleeding history to improve diagnostic accuracy, quantify symptom severity, and predict future bleeding

The ISTH-BAT has been validated for vWD

The ISTH-BAT evaluation study shows its diagnostic utility for inherited platelet disorders with platelet dysfunction, but not for isolated thrombocytopenia




for rare or complex diseases

vWD: von Wilebran disease

#### Step 1 (Clinical presentation): Degree of platelet dysfunction and thrombocytopenia





- Genes underlined: autosomal dominant inheritance
- Genes in bold: X-linked inheritance
- Genes neither underlined nor bold: autosomal recessive inheritance
- Genes with gray background: Syndromic presentations

## When to suspect inherited thrombocytopenia



## Step 1. Clinical presentation

- Family history of thrombocytopenia or hematological malignancies
- Excessive bleeding for platelet counts
- Refractory immune thrombocytopenia
- Von Willebrand disease

Additional findings

## Step 2. Biological features

- Platelet counts and mean platelet volume
- Immature platelet fraction
- Blood smear
- Defects in other cell populations

#### Step 2: Biological features



P	a	te	let
CC	วน	nt	S

 $<100,000/\mu$ l

100,000-150,000/μl (possible)

# Basic coagulation studies


Prothrombin time, activated partial thromboplastin time



Quantification of von Willebrand factor, ristocetin cofactor and coagulant activity of factor VIII

#### Step 2 (biological features): platelet size and IPF





#### Immature Platelet Fraction (IPF)

- Increased in ITP and in inherited thrombopenias (particularly if macrothrombocytopenia)
- Inherited thrombocytopenias tend to have higher IPF than ITP



Collins J, et al. Br J Haematol. 2021;195:25-45

Diseases (ERN EuroBloodNet)



#### Abnormalities in other cell lines

- Anemia: GATA1-related disorders (X-linked), sitosterolemia (ABCG5, ABCG8), GFI1B, GALE
- Neutropenia: disorders related to GATA1, DIAPH1, WAS, GALE
- **Eosinophilia**: characteristic of thrombocytopenia related to *ARPC1B*
- Pancytopenia: congenital amegakaryocytic thrombocytopenia (MPL, THPO, EVI1, HOXA11, MECOM)
- Hematologic malignancies: ETV6, ANKRD26, RUNX1

#### Smear


- Alpha granule deficiency: pathogenic variants in GATA1, GFI1B, NBEAL2, VIPAS39 and VPS33B
- Döhle bodies: MYH9-related disorders



or rare or low prevalence

## Peripheral blood smear and immunofluorescence








Network
 Hematological
 Diseases (ERN EuroBloodNet)

#### Biological phenotype and molecular diagnosis







 Relatively inexpensive and limited number of data to be analyzed

#### Whole exome sequencing (WES)

Identification of new genes

#### Whole genome sequencing (WGS)

 Identification of novel genes, noncoding variants and copy number








#### Classification of inherited thrombocytopenia



	Only thrombocytopenia
	Bernard Soulier síndrome (BSS)
	Monoallelic BSS
	ACTN1-RT
-	Gray platelet syndrome
	Platelet type vWD
	GFI1b-RT
	TUBB1-RT
	ITGA2B/ITGB3-RT
	CYCS-RT
$\vdash$	SLFN14-RT
	FLI1-RT
	IKZF5-RT
-	TRPM7-RT
	TPM4-RT
	PTPRJ-RT
Euro	PRKACG-RT
Refe	
for rare complex	low prevalence G6B

Hematological Diseases (ERN EuroBloodNet)





#### **Unmet need: Diagnosis of ITP is one of exclusion**



#### **All patients**

#### **Potential utility**

#### Unproven / uncertain

Patient history

Family history

Physical examination

Complete blood count and reticulocyte count

Peripheral blood film

Quantitative immunoglobulin level measurement

Blood group (Rh)

HIV

HCV, HBV

Glycoprotein-specific antibody

Antiphospholipid antibodies
Antithyroid antibodies and thyroid function

Pregnancy test in women of childbearing potential

Antinuclear antibodies

Viral PCR for EBV, CMV and parvovirus

H. Pylori

Bone Marrow (selected patients)

Direct antiglobulin test

TPO

Reticulated platelets/ immature platelet fraction

Platelet survival study

Bleeding time

Serum complement

CMV, cytomegalovirus; EBV, Epstein-Barr virus; TPO, thrombopoietin



for rare or low prevalence

Network
 Hematological
 Diseases (ERN EuroBloodNet)

12% of patients who are initially thought to

have primary ITP turn out not to have it

## Clinical and laboratory differences between inherited thrombocytopenia and ITP



#### **Clinical presentation**

	Inherited thrombocytopenia	ITP
Family history	Yes/No	No
Onset	Life-long (young age)	Recent
Bleeding tendency	Mild	Variable
Response to platelet transfusion	Good	Poor
Response to ITP- directed pharmacologic therapy	No	Yes
Fatigue	Absent	Frequently present
Other autoimmune disorder	Not frequent	Frequent

#### **Biological features**

	Inherited thrombocytopenia	ITP
Previous normal platelet count	No	Yes
Blood smear	Variable	Normal or large platelet
Increased immature platelet fraction	Yes	Yes
Platelet count fluctuation	Rare	Frequent


нетатоюдісаі Diseases (ERN EuroBloodNet)

#### However, this difference is not always so clear



Src-related thrombocytopenia: a fine line between a megakaryocyte dysfunction and an immune-mediated disease

Palma-Baqueros V, et al. Blood Adv 2022; 6: 5244-5255








Network
 Hematological
 Diseases (ERN EuroBloodNet)


#### Classification of inherited thrombocytopenia



۲	Only thrombocytopenia
	Bernard Soulier síndrome (BSS
-	Monoallelic BSS
—[	ACTN1-RT
—[	Gray platelet syndrome
—[	Platelet type vWD
—[	GFI1b-RT
—[	TUBB1-RT
—[	ITGA2B/ITGB3-RT
—[	CYCS-RT
—	SLFN14-RT
—	FLI1-RT
—	IKZF5-RT
—	TRPM7-RT
—	TPM4-RT
—	PTPRJ-RT
Euro	PRKACG-RT
Refer Netw	
	G6B

Diseases (ERN EuroBloodNet)








## Case 1. Male diagnosed with childhood ITP with immune deficiency





## Childhood ITP with immune deficiency: Wiskott-Aldrich syndrome



	Bernard Soulier síndrome (BSS)
	Monoallelic BSS
	ACTN1-RT
_	Gray platelet syndrome
	Platelet type vWD
	GFI1b-RT
	TUBB1-RT
	ITGA2B/ITGB3-RT
	CYCS-RT
	SLFN14-RT
	FLI1-RT
	IKZF5-RT
	TRPM7-RT
	TPM4-RT
	PTPRJ-RT
uropean	PRKACG-RT
leference Jetwark	FYB-RT
r rare of low pre	evalence CK G6B

Wiskott Aldrich syndrome: a condition almost exclusively affecting males characterized by thrombocytopenia and bleeding, eczema, combined immunodeficiency, autoimmune manifestations and increased risk of developing tumors at any age.

Suspected diagnosis by family history, physical examination and thrombocytopenia with reduced platelet size, as well as altered antibody production.

Importance of determining the type of mutation and protein expression to predict the evolution of patients (in our case the IVS6+5 g>a mutation).

Transplantation can be considered if there is a suitable donor due to the risk of complications such as intracranial hemorrhage, autoimmune diseases, IgA nephropathy, neoplasms, etc.

disorders

L)

 $\bigcirc)$ 

4.41

411

QT


ia

EuroBleedNet

inarsپانست

## Cases 2&3. ITP diagnosis with skin lesions





Patient 1: 15-year-old male who develops palmoplantar and anogenital hyperkeratosis at 12 months of age

Patient 2: 21-year-old male who develops at 15 months of age diffuse hyperkeratosis on palms and soles (less marked than patient 1)

Patient 1: Diagnosed with ITP (platelets <15x10<sup>9</sup>/l) at 2 years of age and started on corticosteroids; underwent splenectomy at 11 years of age

Patient 2: Diagnosed with ITP (platelets <10x10<sup>9</sup>/l), and exposed for years to steroids

Takeichi T, et al. J Invest Dermatol. 2017;137:2344-53




Diseases (ERN EuroBloodNet)










#### ITP and skin lesions: keratinization disorder with thrombocytopenia





Diseases (ERN EuroBloodNet)

Mutations in *KDSR* cause defects to ceramides, which are vitally important for platelet formation and to maintain skin structure

tional disorders

H9-RD

KRD26

D/AML

rv6-RT

There are certain differences in the clinical phenotypes of keratosis caused by *KDSR* mutations, ranging from diffuse hyperkeratosis to only mild manifestations of minimal involvement in the skin

/IT (MPL)

T (THPO)

COM-RT

(HOXA11)

PH1-RT

Patients with *KDSR* mutations may present with severe thrombocytopenia. Defects in platelet formation and release in the final stage of thrombopoiesis may be the primary cause of thrombocytopenia in patients with *KDSR* mutations

RC-RT

terolemia

When patients with *KDSR* mutations have repeated bleeding due to thrombocytopenia, which is lifethreatening, hematopoietic stem cell transplantation should be considered




## Classification of inherited thrombocytopenia



ļ.	Only thrombocytopenia
$\vdash$	Bernard Soulier síndrome (BSS)
$\vdash$	Monoallelic BSS
$\vdash$	ACTN1-RT
$\vdash$	Gray platelet syndrome
$\vdash$	Platelet type vWD
$\vdash$	GFI1b-RT
$\perp$	TUBB1-RT
┝	ITGA2B/ITGB3-RT
-	CYCS-RT
-	SLFN14-RT
$\perp$	FLI1-RT
╟	IKZF5-RT
┝	TRPM7-RT
$\perp$	TPM4-RT
$\perp$	PTPRJ-RT
E	luro pean PRKACG-RT
L	Ver present the second
co	omplex of the control
He Di	ematologicai iseases (ERN EuroBloodNet)


٢	Wiskott-Aldrich; XLT
=	
	SD Paris-Trousseau/Jacobsen (FLI1
	Thrombocytopenia absent radii
	GATA1-RT
	ARPC1B-RT
	Stormorken/York syndromes
	Takenouchi-Kosaki syndrome
	KDSR-RT
	ACTB-RT
	FLNA-RT
	MPIG6B-RT
	GALE-RT
	GNE-RT





#### Spanish group of inherited platelet disorders: inherited thrombocytopenia








**MHEMO** 

leference

Network
for rare or low prevalence

## Case 4. ITP with deafness and end-stage renal disease






complex diseases

Network
Hematological
Diseases (ERN EuroBloodNet)



#### ITP with deafness and end-stage renal disease: MYH9-RD





orders MYH9-RD: most frequent cause of inherited macrothrombocytopenia Mean age at diagnosis: 31 years Autosomal dominant, but 35% of cases are sporadic 35% of patients are previously misdiagnosed with ITP 50% of patients have hepatic alterations 50% progressive sensorineural hearing loss (age at onset 31 years) 30% nephropathy (age of onset 30 years; most evolve to bilateral renal disease in 5-10 years) 18% presentile cataracts often bilateral (mean age 21 years)

#### Case 5. Myelodysplastic syndrome in 40-year-old patient



40-year-old patient being followed up for bicytopenia (anemia and thrombocytopenia < 20x109/l) in the last 3 years.

No platelet response to intravenous immunoglobulins or steroids.

marrow studies a diagnosis of refractory cytopenia with megakaryocyte dysplasia and intermediate risk IPSS-R (4 points) is established.

karyotype, MDS/LAM-After several bone related gene panel).

matched sibling

Patient has an HLA-

WHO, 2022

#### Myeloid neoplasms with germline predisposition and pre-existing platelet disorder


- Germline RUNX1 P/LP variant<sup>a</sup> (familial platelet disorder with associated myeloid malignancy, FPD-MM)
- Germline ANKRD26 P/LP varianta (Thrombocytopenia 2)
- Germline ETV6 P/LP varianta (Thrombocytopenia 5)

No findings in genetic

studies (FISH,

Khoury, J.D., et al. Leukemia 2022; 36, 1703-1719

#### ANKRD26








Family screening: de novo mutation



#### Inherited platelet disorders predisposing to myeloid neoplasms




#### **FPD/AML (48%)**




Latger-Cannard V, et al. Orphanet J Rare Dis. 2016;11:49

## **ANKRD26 (9%)**



Noris P, et al. Blood. 2013;122:1987-9

## ETV6 (28%)



Feurstein S, et al. Int J Hematol. 2017;106:189-195

		FPD/AML (RUNX-1)	ANKRD26	ETV6
•••	Mean platelet count (x10°/l)	99	46	81
	Mean age at the diagnosis of malignacy (years)	30	49	20

DISEASES (ERN EuroBloodNet)

## Myelodysplastic syndrome in 40-year-old patient: ANKRD26-RD



disorders


<u>1ars</u>

	Only thrombocytopenia  Bernard Soulier síndrome (BSS)	The presentation of inherited forms of thrombocytopenia and predisposition to hematologic malignancies (mutations in RUNX1, ANKRD26 or ETV6) is very similar: mild-moderate thrombocytopenia, normal platelet size, autosomal		
	Monoallelic BSS	dominant inheritance and predisposition to malignancy.		
	ACTN1-RT			
	Gray platelet syndrome	In all three disorders the bone marrow examination shows a normal or		
	Platelet type vWD	increased number of megakaryocytes with dysplastic features such as small		
	GFI1b-RT	size and hypolobulated nuclei.		
	TUBB1-RT			
	ITGA2B/ITGB3-RT	A clinically relevant difference is a normal platelet function in ANKRD26- and		
	CYCS-RT	ETV6-related disorders, whereas platelet dysfunction in RUNX1 may be		
	SLFN14-RT	clinically associated with the presence of bleeding.		
	FLI1-RT			
	IKZF5-RT	While ANKRD26- and RUNX1-associated malignancies are predominantly		
	TRPM7-RT	myeloid, those associated with ETV6 are predominantly lymphoid.		
	TPM4-RT			
	PTPRJ-RT			
Europea Referen	PRKACG-RT	It is important to perform family screening once a case is detected, particularly if the patient is a candidate for allo-transplantation from a related donor.		
Netw ork	prevalence FYB-RT			
complex miseu	CCD			

Diseases (ERN EuroBloodNet)


## Case 6. ITP progressing to dysplasia/aplasia





#### ITP progressing to dysplasia/aplasia: Congenital amegakaryocytic thrombocytopenia





Diseases (ERN EuroBloodNet)

CAMT (congenital amegakaryocytic thrombocytopenia): Inherited marrow failure not associated with other malformations.

Bi-allelic mutations in the receptor (c-mpl), and less frequently in the ligand (thrombopoietin, TPO), alter the signaling of this axis, essential for the maintenance and self-renewal of multipotent cells and for differentiation into megakaryocytes.

Thrombocytopenia at birth progresses to bone marrow aplasia.

While allogeneic transplantation is the only curative option in cases due to MPL mutations, Romiplostim has been shown to have optimal responses in the less frequent cases of patients with biallelic mutations in TPO.



al disorders

20)

(A 44)


7 ( 1 1 )

RT

mia

#### Case 7. Thrombocytopenia and sensorineural hearing loss since childhood





MYH9 mutations were ruled out.

Two bone marrow biopsies and one liver biopsy were performed without reaching a diagnosis.


He has two children, both with thrombocytopenia + neutropenia + deafness.


28-year-old patient referred for moderate thrombocytopenia and neutropenia.

sensorineural hearing loss since childhood.

He presented

#### DIAPH1








for rare or low prevalence complex diseases

Network
 Hematological
 Diseases (ERN EuroBloodNet)

#### Thrombocytopenia and sensorineural hearing loss since childhood: DIAPH1-RT



disorders




DIAPH1-RD: manifestations characterized by macrothrombocytopenia, neutropenia, and hearing loss.

Not associated with renal disease, cataracts, or neutrophil inclusions, which differentiates DIAPH1-RD from MYH9-RD, which also presents with

macrothrombopenia and deafness.


Eltrombopag partially rescues deficient proplatelet formation of DIAPH1-RD MK cultures, and administration for short periods of TPO-RA may temporarily correct platelet counts.



Westbury SK, et al. Blood Adv. 2018;2:2341-2346

#### **Case 8. Thrombocytopenia and xanthomas**





**Familial** hypercholesterolemia with xanthomas.


**Complained from** 

46 year old patient referred for macrothrombocytopenia.


arthralgias, arthritis and mild cutaneous diathesis.

ABCG5

p.F630L fs8X; c.1890delT



p.T305R; c.914C>G



On examination she presented xanthelasmas (4 surgical interventions).

Plasma sterols **Normal Patient** range Sitosterol (µM) 688 <10 Campesterol (µM) <3 170 β-Colestanol (μM) 31 2-13 Cholesterol (mM) 2-7 3



Hematological Diseases (ERN EuroBloodNet)








## Thrombocytopenia and xanthomas: Sitosterolemia





## Suspecting inherited thrombocytopenia



Consider a form of thrombocytopenia to be hereditary when there is no previous evidence of normal blood counts or other causes for it.

## From theory

Family history

History of bleeding since infancy; more bleeding than expected by count

Presence of other additional defects

Large or dysmorphic platelets or megakaryocyte dysplasia

complex diseases

Network
 Hematological
 Diseases (ERN EuroBloodNet)

MHEMO

## To practice

Many forms are recessive. High percentage of de novo mutations

In many cases patients do not bleed and there is no alteration of platelet functionality.

There is a percentage of thrombocytopenia without other additional manifestations

We still do not give the importance we should give to the peripheral blood smear

38% in ANKRDD26-RT

(Noris P, et al. Blood. 2011;117:6673-80)

62% in Bernard Soulier

(Sanchez-Guiu I, et al. Orphanet J Rare Dis. 2014;9:213)

The percentage of patients with inherited thrombocytopenias diagnosed with ITP is very high

35% in MYH9-RD (Rabbolini DJ, et al. Platelets. 2018;29:793-800)

31% of different forms (57/181); 77% inappropriately treated, and 26% splenectomized (Noris P, et al. Haematologica. 2014;99:1387-94)





## We must offer the right treatment to patients



#### **Bleeding**

• Platelet transfusions, antifibrinolytic agents, desmopressin

#### Thrombopoietin receptor agonists

- Eltrombopag: MYH9-RD, Wiskott-Aldrich, DIAPH1-RD
- Romiplostim: THPO mutations

#### Allogeneic hematopoietic progenitor transplantation

- Congenital amegakaryocytic thrombopenia; Radioulnar synostosis with amegakaryocytic thrombocytopenia
- Wiskott-Aldrich
- Hematologic malignancies predisposing to hematologic malignancies (ANKRD26-RD, RUNX1-RD, ETV6-RD)

#### **Extra-hematological manifestations (e.g. MYH9-RD)**

- Renin-angiotensin or ARAII blockade
- Cochlear implants
- Cataract surgery


#### **Predisposition to leukemias**

- Family screening
- Genetic counseling
- Regular blood/marrow and cytogenetic testing



#### Suspecting and reaching a correct diagnosis is a vital approach in providing patients with appropriate management and prevent unnecessary treatments









Congenital amegakaryocytic thrombocytopenia





## Thank you



for rare or low prevalence complex diseases

Network
 Hematological
 Diseases (ERN EuroBloodNet)

#### Take home messages



- 1. Inherited thrombocytopenia is a heterogeneous spectrum of disorders ranging from isolated mild thrombocytopenia to forms that predispose to additional serious diseases.
- 2. Inherited thrombocytopenia is under-recognized; when it presents with isolated thrombocytopenia, it is often misdiagnosed as ITP, leading to inappropriate treatment.
- 3. In clinical practice, the recognition of lifelong thrombocytopenia not attributable to other causes is sufficient to investigate its genetic origin; a precise diagnosis has an impact on patient management and prognosis in many cases.





